Hyponatremia is associated with shorter cancer-specific survival in patients with metastatic renal cell carcinoma (RCC) treated with molecular targeted therapy, Japanese researchers reported online in the International Journal of Urology.
In a retrospective study of 87 patients with metastatic RCC treated with sorafenib or sunitinib as first-line treatment, Atsunari Kawashima, MD, of Osaka University Graduate School of Medicine, and colleagues found that median cancer-specific survival times were 8.8 months for patients with severe and mild hyponatremia compared with 32.6 months for patients with normal natremia. In multivariate analysis, severe and mild hyponatremia were associated with a significant sixfold and threefold increased risk of cancer-specific mortality, respectively.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.